Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: A multicenter phase II trial

Annals of Oncology

Volumn 18, Issue 4, 2007, Pages 745-751

  Boeck, S ^a   Weigang Kohler K ^b   Fuchs, M ^c   Kettner, E ^d   Quietzsch, D ^e   Trojan, J ^f   Stotzer O ^g   Zeuzem, S ^h   Lordick, F ⁱ   Kohne C H ^j   Kroning H ^k   Steinmetz, T ^l   Depenbrock, H ^m   Heinemann, Volker ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Municipal Hospital Nürnberg Nord   (Germany)

^c KLINIKUM BOGENHAUSEN   (Germany)

^d Hospital Magdeburg   (Germany)

^e Hospital Chemnitz   (Germany)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g Oncological Practice   (Germany)

^h SAARLAND UNIVERSITY   (Germany)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^j UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^k Practice for Oncology   (Germany)

^l Practice for Gynecological Oncology   (Germany)

^m LILLY DEUTSCHLAND GMBH   (Germany)

more..

Author keywords

Gemcitabine; Multitargeted antifolate; Pancreatic cancer; Pemetrexed; Second line therapy

Indexed keywords

CA 19-9 ANTIGEN; CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; GEMCITABINE; OXALIPLATIN; PEMETREXED;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOKALEMIA; INFECTION; INOPERABLE CANCER; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE;

EID: 34047101956     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl463     Document Type: Article

References (27)

1. Herbst RS, Bajorin DF, Bleiberg H et al. Clinical cancer advanced 2005: major research advanced in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J Clin Oncol 2006; 24: 190-205.
2. Burris HA, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403-2413.
3. Heinemann V. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol 2002; 29 (Suppl 20): 9-16.
4. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinicals trials group [NCIC-CTG]. Proc Am Soc Clin Oncol 2005; 23: (Abstr 1).
5. Cunningham D, Chau I, Stocken D et al. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer Suppl 2005; 3: (Abstr PS11).
6. Oettle H, Pelzer U, Stieler J et al. Oxaliplatin/folinic acid/ 5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). Proc Am Soc Clin Oncol 2005; 23: (Abstr 4031).
7. Tsavaris N, Kosmas C, Skopelitis H et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Invest New Drugs 2005; 23: 369-375.
8. Cantore M, Rabbi C, Fiorentini G et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology 2004; 67: 93-97.
9. Demols A, Peeters M, Polus M et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: A phase II study. Br J Cancer 2006; 94: 481-485.
10. Reni M, Pasetto L, Aprile G et al. Raltitrexed-eloxantin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer 2006; 94: 785-791.
11. Oettle H, Arnold D, Esser M et al. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 2000; 11: 635-638.
12. Milella M, Gelibter A, Di Cosimo S et al. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004; 101: 133-138.
13. Jacobs AD, Burris HA, Rivkin S et al. A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer. Report from a North-American multi-center study. Proc Am Soc Clin Oncol 2004; 22: (Abstr 4013).
14. Ulrich-Pur H, Rüderer M, Kornek GV et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 2003; 88: 1180-1184.
15. Blaszkowsky LS, Kulke KH, Ryan DP et al. A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancer. Proc Am Soc Clin Oncol 2005; 23: (Abstr 4099).
16. Shih C, Chen VJ, Gossett LS et al. LY231514, a pyrrolo[2,3-d]-pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997; 57: 1116-1123.
17. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
18. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
19. Miller KD, Picus J, Blanke C et al. Phase II study of the multitargeted antifolate LY231514 (ALIMTA®, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol 2000; 11: 101-103.
20. Oettle H, Richards D, Ramanathan RK et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005; 16: 1639-1645.
21. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
23. Rollins KD, Lindley C. Pemetrexed: A multitargeted antifolate. Clin Ther 2005; 27: 1343-1382.
24. Louvet C, Labinaca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23: 3509-3516.
25. Ueno H, Okada S, Okusaka T, Ikeda M. Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 2000; 59: 296-301.
26. Mancuso-Petricca A, Saletti P, Tronconi MC et al. The efficacy of fluoropyrimidine-based second line chemotherapy in advanced and metastatic pancreatic cancer: Results of an ongoing Italian/Swiss multicenter survey. Ann Oncol 2006; 17 (Suppl 9): Ix323 (Abstr 1131P).
27. Scagliotti GV. Pemetrexed plus carboplatin or oxaliplatin in advanced non-small cell lung cancer. Semin Oncol 2005; 32 (Suppl 2): 5-8.